AU2016296321B2 - Anti-TfR antibodies and their use in treating proliferative and inflammatory disorders - Google Patents
Anti-TfR antibodies and their use in treating proliferative and inflammatory disorders Download PDFInfo
- Publication number
- AU2016296321B2 AU2016296321B2 AU2016296321A AU2016296321A AU2016296321B2 AU 2016296321 B2 AU2016296321 B2 AU 2016296321B2 AU 2016296321 A AU2016296321 A AU 2016296321A AU 2016296321 A AU2016296321 A AU 2016296321A AU 2016296321 B2 AU2016296321 B2 AU 2016296321B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- seq
- ser
- protein
- tfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306192.4 | 2015-07-22 | ||
| EP15306192 | 2015-07-22 | ||
| PCT/EP2016/067465 WO2017013230A1 (en) | 2015-07-22 | 2016-07-21 | ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016296321A1 AU2016296321A1 (en) | 2018-01-25 |
| AU2016296321B2 true AU2016296321B2 (en) | 2022-09-08 |
Family
ID=53776520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016296321A Active AU2016296321B2 (en) | 2015-07-22 | 2016-07-21 | Anti-TfR antibodies and their use in treating proliferative and inflammatory disorders |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11230605B2 (OSRAM) |
| EP (1) | EP3325509B1 (OSRAM) |
| JP (1) | JP6858185B2 (OSRAM) |
| KR (1) | KR102690998B1 (OSRAM) |
| CN (1) | CN107849136B (OSRAM) |
| AU (1) | AU2016296321B2 (OSRAM) |
| CA (1) | CA2992509C (OSRAM) |
| CY (1) | CY1123941T1 (OSRAM) |
| DK (1) | DK3325509T3 (OSRAM) |
| ES (1) | ES2860988T3 (OSRAM) |
| HR (1) | HRP20210393T1 (OSRAM) |
| HU (1) | HUE053296T2 (OSRAM) |
| IL (1) | IL257065B (OSRAM) |
| LT (1) | LT3325509T (OSRAM) |
| MX (1) | MX2018000569A (OSRAM) |
| PL (1) | PL3325509T3 (OSRAM) |
| PT (1) | PT3325509T (OSRAM) |
| RS (1) | RS61586B1 (OSRAM) |
| RU (1) | RU2737637C2 (OSRAM) |
| SI (1) | SI3325509T1 (OSRAM) |
| SM (1) | SMT202100134T1 (OSRAM) |
| WO (1) | WO2017013230A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY194184A (en) | 2015-05-04 | 2022-11-17 | Cytomx Therapeutics Inc | Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof |
| FR3062213B1 (fr) | 2017-01-20 | 2021-02-26 | Endodiag | Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| SG11202100934PA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| WO2021092482A1 (en) * | 2019-11-06 | 2021-05-14 | The Regents Of The University Of California | Compositions and methods for transferrin receptor 1 targeting |
| US20230113823A1 (en) * | 2020-01-31 | 2023-04-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| AU2022309028A1 (en) | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CR20240139A (es) | 2021-09-01 | 2024-06-14 | Biogen Ma Inc | Anticuerpos del receptor antitransferrina y usos de los mismos |
| US20240376222A1 (en) * | 2021-09-13 | 2024-11-14 | The Board Of Regents Of The University Of Texas System | Tfr antigen binding proteins and uses thereof |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| AU2023404617A1 (en) * | 2022-12-02 | 2025-05-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-tfr1 antibodies and uses thereof |
| CN120958020A (zh) | 2023-03-24 | 2025-11-14 | 戴纳立制药公司 | Aβ靶向蛋白和使用方法 |
| EP4477236A1 (en) | 2023-06-14 | 2024-12-18 | Inatherys | Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics |
| TW202517685A (zh) * | 2023-10-26 | 2025-05-01 | 美商百健Ｍａ公司 | 抗運鐵蛋白受體抗體及其用途 |
| WO2025140522A1 (en) * | 2023-12-29 | 2025-07-03 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-tfr1 antibodies, preparation methods and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005111082A1 (en) * | 2004-04-30 | 2005-11-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-tfr antibody. |
| WO2014020140A1 (en) * | 2012-08-02 | 2014-02-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of transferrin receptor antagonist for the treatment of thalassemia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4434156A (en) | 1981-10-26 | 1984-02-28 | The Salk Institute For Biological Studies | Monoclonal antibodies specific for the human transferrin receptor glycoprotein |
| ES2694002T3 (es) * | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| JP4741838B2 (ja) | 2002-07-31 | 2011-08-10 | シアトル ジェネティクス，インコーポレーテッド | 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用 |
| WO2005011082A2 (en) | 2003-07-23 | 2005-02-03 | Univeral Infusion Technology | Drive motor transmission system |
| WO2005121179A2 (en) * | 2004-06-07 | 2005-12-22 | Raven Biotechnologies, Inc. | Transferrin receptor antibodies |
| EP2439273B1 (en) * | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| FR2953841B1 (fr) * | 2009-12-16 | 2011-12-30 | Centre Nat Rech Scient | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
| DK2918603T3 (en) * | 2012-11-08 | 2018-10-15 | Univ Miyazaki | ANTIBODY STANDING TO SPECIFICALLY RECOGNIZE TRANSFERRIN RECEPTOR |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
-
2016
- 2016-07-21 MX MX2018000569A patent/MX2018000569A/es unknown
- 2016-07-21 SI SI201631117T patent/SI3325509T1/sl unknown
- 2016-07-21 IL IL257065A patent/IL257065B/en unknown
- 2016-07-21 DK DK16744353.0T patent/DK3325509T3/da active
- 2016-07-21 CN CN201680040714.2A patent/CN107849136B/zh active Active
- 2016-07-21 CA CA2992509A patent/CA2992509C/en active Active
- 2016-07-21 HU HUE16744353A patent/HUE053296T2/hu unknown
- 2016-07-21 RU RU2018106364A patent/RU2737637C2/ru active
- 2016-07-21 RS RS20210280A patent/RS61586B1/sr unknown
- 2016-07-21 LT LTEP16744353.0T patent/LT3325509T/lt unknown
- 2016-07-21 PL PL16744353T patent/PL3325509T3/pl unknown
- 2016-07-21 HR HRP20210393TT patent/HRP20210393T1/hr unknown
- 2016-07-21 PT PT167443530T patent/PT3325509T/pt unknown
- 2016-07-21 US US15/746,590 patent/US11230605B2/en active Active
- 2016-07-21 WO PCT/EP2016/067465 patent/WO2017013230A1/en not_active Ceased
- 2016-07-21 JP JP2018522867A patent/JP6858185B2/ja active Active
- 2016-07-21 ES ES16744353T patent/ES2860988T3/es active Active
- 2016-07-21 SM SM20210134T patent/SMT202100134T1/it unknown
- 2016-07-21 KR KR1020187004745A patent/KR102690998B1/ko active Active
- 2016-07-21 EP EP16744353.0A patent/EP3325509B1/en active Active
- 2016-07-21 AU AU2016296321A patent/AU2016296321B2/en active Active
-
2021
- 2021-03-09 CY CY20211100200T patent/CY1123941T1/el unknown
- 2021-12-09 US US17/546,208 patent/US12037408B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005111082A1 (en) * | 2004-04-30 | 2005-11-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-tfr antibody. |
| WO2014020140A1 (en) * | 2012-08-02 | 2014-02-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of transferrin receptor antagonist for the treatment of thalassemia |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12037408B2 (en) | Method of treating a tumor using anti-TfR antibodies | |
| AU2020286284B2 (en) | Novel anti-CD39 antibodies | |
| AU2008232409B2 (en) | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof | |
| CN109476742B (zh) | Tl1a抗体及其用途 | |
| KR102847971B1 (ko) | 항체-약물 컨쥬게이트 및 이의 암 치료 용도 | |
| BR122020025629B1 (pt) | Anticorpo anti-ox40, composição farmacêutica que compreende o mesmo e método in vitro para a produção do dito anticorpo | |
| CA2934965A1 (en) | Novel anti-baff antibodies | |
| CN117794948A (zh) | 结合人纤维蛋白或纤维蛋白原γC结构域的抗体及其使用方法 | |
| KR20160010391A (ko) | Cd20 및 cd95에 결합하는 재조합 이중특이성 항체 | |
| EP4298125A1 (en) | Antibodies that bind cd123 and gamma-delta t cell receptors | |
| WO2021259335A1 (en) | Human monoclonal antibodies against tigit for immune related diseases | |
| CA3254085A1 (en) | KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE | |
| US20250188163A1 (en) | Gprc5d antibodies with enhanced effector function and uses thereof | |
| HK1256088B (en) | Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders | |
| BR112018000650B1 (pt) | Anticorpos anti-trf e sua utilização no tratamento de transtornos proliferativos e inflamatórios | |
| WO2024251154A1 (zh) | 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途 | |
| WO2024251154A9 (zh) | 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途 | |
| WO2024175030A1 (zh) | 抗Nectin-4抗体和包含其的多特异性抗体 | |
| CN117295762A (zh) | 抗cd122抗体及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |